Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss
This article was originally published in The Pink Sheet Daily
Executive Summary
Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.